Press release
Caris Life Sciences and Moderna Announce Multi-Year Strategic Partnership to Advance mRNA-Based Oncology Therapeutics
Partnership enables Moderna to leverage Caris' vast library of de-identified, multi-modal data and analytics capabilities to accelerate precision medicine and
About this update from Moderna, Inc.
[{"type":"text","content":"Partnership enables Moderna to leverage Caris' vast library of de-identified, multi-modal data and analytics capabilities to accelerate precision medicine and the delivery of novel medicines to patients\nIRVING, Texas, Oct. 24, 2023 /PRNewswire/ -- Caris Life Sciences®(Caris), the leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition using molecular science and AI, today announced a new agreement with Moderna (NASDAQ:MRNA) in support of Moderna's oncology and novel therapeutics initiatives.\n\n \n \n \n \n \n \n\n \nCaris Life Sciences and Moderna Announce Multi-Year Strategic Partnership to Advance mRNA-Based Oncology TherapeuticsThrough this multi-year agreement, Moderna will leverage Caris' vast library of de-identified, multi-modal data solutions derived from whole exome sequencing, whole transcriptome sequencing and protein analyses along with claims data to enhance development strategies for Moderna's oncology pipeline, including facilitation of optimal clinical trial design, discovery of novel biomarkers and characterization of resistance mechanisms.\n\"Partnering with Caris Life Sciences will support Moderna's oncology portfolio with clinico-genomics data from Caris' industry-leading and comprehensive suite of integrated precision medicine capabilities,\" stated Praveen Aanur, MD, MPH, MBA, Vice President, Oncology Therapeutic Area Head of Moderna.\n\"We are thrilled to partner with Moderna to impact and advance the field of cancer treatment with mRNA medicines, with a common goal of improving patient lives,\" said David Spetzler, MS, PhD, MBA, President of Caris Life Sciences. \"The aggregate strength of our combined molecular, data science and therapeutics technologies will support the predictive modeling of patient responses to therapies, and more generally, may help improve the probability of technical and regulatory success of Moderna's innovative medicines.\"\nAs the pioneer in precision medicine and molecular profiling, Caris has created the largest clinico-genomic database coupled with cognitive computing to unravel the molecular complexity of disease. Caris was the first in the industry to provide Whole Exome Sequencing DNA coverage and Whole Transcriptome Sequencing RNA...